Samsung Biologics and Baxter Expand Manufacturing Partnership with $223M Deal

1. Deal Value: Samsung Biologics and Baxter Healthcare have agreed to a manufacturing deal worth $223 million.
2. Additional Payment: Baxter Healthcare will pay Samsung Biologics an extra $208 million to manufacture certain drug products.
3. Duration: The deal extends until the end of 2034.
4. Partnership: This agreement expands the existing partnership between Samsung Biologics and Baxter Healthcare.
5. Manufacturing Facility: Samsung Biologics' Plant 4 facility is involved in this deal, which has contributed to the company's earnings growth in the first quarter of 2024.